NCT06462248View on ClinicalTrials.gov

Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Lymphoma, NonhodgkinLeukemia, Lymphocytic
Interventions
DRUG

CUCART19

anti-CD19 chimeric antigen receptor modified T-cell (CAR-T)

Trial Locations (1)

Unknown

RECRUITING

Prince of Wales Hospital, Hong Kong

All Listed Sponsors
collaborator

Hong Kong Children's Hospital

OTHER

lead

Chi Kong Li

OTHER